You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer
Not yet recruiting
  • Triple Negative Breast Cancer
  • HER2-positive Breast Cancer
    • (no location specified)
    2022-02-15
    Feb 15, 2022
    W
    Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity - 2021
    Terminated
    • Triple Negative Breast Neoplasms
    • Saint Louis, Missouri
      Washington University School of Medicine
    2022-01-06
    Jan 6, 2022
    F
    Reverse Triple Negative Immune Resistant Breast Cancer
    Recruiting
    • Triple-negative Breast Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    2022-04-01
    Apr 1, 2022
    G
    Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
    Recruiting
    • Early Small (cT1N0) Triple Negative Breast Cancer
    • Villejuif, France
      Gustave Roussy
    2022-01-17
    Jan 17, 2022
    U
    Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR - 2020
    Terminated
    Has Results
    • Breast Neoplasms
    • Triple Negative Breast Neoplasms
    • Chicago, Illinois
    • +1 more
    2022-01-31
    Jan 31, 2022
    S
    Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
    Recruiting
    • Triple Negative Breast Cancer
    • Deferoxamine Plus Chemotherapy
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    2022-03-28
    Mar 28, 2022
    U
    Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
    Active, not recruiting
    • Triple Negative Breast Neoplasms
    • Breast Cancer
    • Chicago, Illinois
      University of Chicago
    2021-11-12
    Nov 12, 2021
    M
    Study Assessing QBS72S For Treating Brain Metastases of Triple Negative Breast Cancer
    Not yet recruiting
    • Brain Metastases
    • Breast Cancer
    • Palo Alto, California
      Stanford Cancer Institute
    2022-03-22
    Mar 22, 2022
    U
    Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
    Active, not recruiting
    • Triple Negative Breast Cancer
    • Chicago, Illinois
      University of Illinois
    2022-01-28
    Jan 28, 2022
    A
    Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
    Recruiting
    • Triple Negative Breast Cancer (TNBC)
    • Changchun, Jilin, China
      Aiping Shi
    2021-10-11
    Oct 11, 2021
    C
    Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
    Active, not recruiting
    • Triple Negative Breast Neoplasms
    • 350 mg leronlimab
    • +4 more
    • San Francisco, California
    • +1 more
    2022-03-18
    Mar 18, 2022
    C
    Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients
    Recruiting
    • Triple Negative Breast Cancer
      • Clermont-Ferrand, France
        Centre Jean PERRIN
      2022-01-12
      Jan 12, 2022
      G
      Bisphenol and Phthalate Exposures in Triple Negative Breast Cancer
      Not yet recruiting
      • Triple Negative Breast Cancer
      • urine collection
      • Washington, District of Columbia
        Milken Institute School of Public Health, George Washington Univ
      2022-03-14
      Mar 14, 2022
      W
      Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
      Active, not recruiting
      • Triple Negative Breast Cancer
      • +3 more
      • Saint Louis, Missouri
        Washington University School of Medicine
      2022-03-14
      Mar 14, 2022
      A
      Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
      Not yet recruiting
      • Breast Cancer Triple Negative
      • (no location specified)
      2021-11-17
      Nov 17, 2021
      P
      Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
      Recruiting
      • Breast Cancer
      • Breast Neoplasms
      • Portland, Oregon
        Providence Portland Medical Center
      2022-01-31
      Jan 31, 2022
      F
      Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
      Not yet recruiting
      • Advanced Triple Negative Breast Cancer
      • Apatinib Mesylate
      • Albumin-Bound Paclitaxel
      • Fuzhou, Fujian, China
        Fujian Cancer Hospital
      2021-08-18
      Aug 18, 2021
      U
      ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer - 2021
      Terminated
      Has Results
      • Triple Negative Breast Cancer
      • Akt/ERK Inhibitor ONC201
      • Methionine-Restricted Diet
      • Madison, Wisconsin
        University of Wisconsin Carbone Cancer Center
      2022-02-11
      Feb 11, 2022
      T
      Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
      Suspended
      • Triple Negative Breast Cancer
      • Anthracycline-refractory TNBC
      • Houston, Texas
        Houston Methodist Cancer Center
      2022-03-28
      Mar 28, 2022
      F
      Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
      Recruiting
      • Triple Negative Breast Cancer
      • Personalized treatment guided by mini-PDX and RNA sequencing
      • +5 more
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      2021-12-27
      Dec 27, 2021
      I
      Imaging Performance Assessment of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Metastatic Triple Negative Breast Cancer Patients
      Recruiting
      • Triple Negative Breast Cancer
      • 89Zr-TLX250 PET/CT
      • Saint-Herblain, France
        ICO René Gauducheau
      2021-10-18
      Oct 18, 2021
      B
      Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer - 2020
      Completed
      • Triple Negative Breast Cancer
      • Glucose
      • Dallas, Texas
        Baylor University Medical Center
      2021-10-07
      Oct 7, 2021
      W
      Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
      Withdrawn
      • Triple Negative Breast Cancer
      • +2 more
      • Personalized synthetic long peptide vaccine (Poly ICLC)
      • Poly ICLC
      • (no location specified)
      2022-03-09
      Mar 9, 2022
      U
      CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
      Not yet recruiting
      • Metastatic Triple Negative Breast Cancer
      • PLD Chemotherapy
      • +2 more
      • (no location specified)
      2022-03-29
      Mar 29, 2022
      M
      Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) - 2020
      Completed
      Has Results
      • Metastatic Triple Negative Breast Cancer
      • pembrolizumab
      • +4 more
      • (no location specified)
      2021-11-09
      Nov 9, 2021